Evidence map›Paper›PMID 31432366›Full record

ArticleBreast cancer research and treatment2019

Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.

Chidananda M Siddappa, Sreeraj G Pillai, Jackie Snider, Patsy Alldredge, Kathyrn Trinkaus, Mark A Watson, Rebecca Aft

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chidananda M SiddappaDepartment of Surgery, Washington University School of Medicine, Box 8109, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Sreeraj G PillaiDepartment of Surgery, Washington University School of Medicine, Box 8109, 660 South Euclid Avenue, St. Louis, MO, 63110, USA.
Jackie SniderDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Patsy AlldredgeDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Kathyrn TrinkausDivision of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Mark A WatsonDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Rebecca AftDepartment of Surgery, Washington University School of Medicine, Box 8109, 660 South Euclid Avenue, St. Louis, MO, 63110, USA. aftr@wustl.edu.ORCID http://orcid.org/0000-0001-8569-7131

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLSR01CA172623 · NCI · WASHINGTON UNIVERSITY · PI AFT, REBECCA L., WATSON, MARK A. · 2013 to 2017
$2.0M
NCATS NIH HHS UL1 TR002345NCI NIH HHS R01 CA172623NIH HHS CA172623
6 · The paper itself

Abstract

purposeDisseminated tumor cells (DTCs) in the BM of breast cancer patients predict early disease relapse, but the molecular heterogeneity of these cells is less well characterized. Expression of a 46-gene panel was used to detect DTCs and classify patient BM samples to determine whether a composite set of biomarkers could better predict metastatic relapse.

methodsUsing a high-throughput qRT-PCR assay platform, BM specimens collected from 70 breast cancer patients prior to neoadjuvant therapy were analyzed for the expression of 46 gene transcripts. Gene expression was scored positive (detectable) relative to a reference pool of 16 healthy female control BM specimens. To validate findings from a subset of 28 triple-negative breast cancer (TNBC) patients in the initial 70 patient cohort, an independent set of pre-therapeutic BM specimens from 16 TNBC patients was analyzed.

resultsExpression of each of the 46 gene transcripts was highly variable between patients. Individual gene expression was detected in 0-84% of BM specimens analyzed and all but two patient BM specimens expressed at least one transcript. Among a subset of 28 patients with TNBC, positivity of one or more of eight transcripts correlated with time to distant relapse (p = 0.03). In an independent set of 16 triple-negative patient BM samples, detection of five of these same eight gene transcripts also correlated with time to distant relapse (p = 0.03) with a positive predictive value of 89%.

conclusionsWe identified a set of gene transcripts whose detection in the BM of TNBC patients, prior to any treatment intervention, predicts time to first distant relapse, thus identifying a TNBC patient population which requires additional treatment intervention. Because these genes are presumably expressed in populations of DTCs and many encode proteins that are known therapeutic targets (e.g., ERBB2), these results also suggest a potential approach for targeted DTC therapy to mitigate distant metastases in TNBC.

Indexed as

Biomarkers, TumorTranscriptomeBone MarrowFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateNeoplasm GradingNeoplasm MetastasisNeoplasm StagingNeoplastic Cells, CirculatingPrognosisTriple Negative Breast NeoplasmsTumor BurdenBiomarkers, TumorDisseminated tumor cellsGene expressionMetastasisTargeted therapyTriple-negative breast cancer

Identifiers

PMID31432366
PMCPMC6797655

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.